Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial)

American Journal of Cardiology

Volumn 78, Issue 2, 1996, Pages 142-147

  Becker, Richard C ^a   Cannon, Christopher P ^b   Bovill, Edwin G ^b   Tracy, Russell P ^b   Thompson, Bruce ^b   Knatterud, Genell L ^b   Randall, Amy ^b   Braunwald, Eugene ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE MB; FIBRINOGEN; NITRATE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

EID: 0030015790     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)90386-0     Document Type: Article

References (30)

1. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invesr 1988;58:249-261.
2. Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992;12:206-211.
3. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
4. Hansson GK, Helm J, Jonasson L. Detection of activated T-lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-175.
5. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990;65:297-302.
6. Liuzzo G, Biasucci LM, Gallimore R, Grille RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424.
7. Fatah K, Hamsten A, Blomback B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein. serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992;68:130-135.
8. The TIMI III B Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction: results of the TIMI III B Trial. Circulation 1994;89:1545-1556.
9. Clauss A. Gerinnungsphysioloische Schnellmethode zur bestimung des fibrinogens. Acta Haematol (Basel) 1957;17:237-246.
10. Geffken D, Keating F, Kennedy M, Cornell E, Bovill E, Tracy R. The measurement of fibrinogen in population-based research: studies on instrumentation and methodology. Arch Pathol Lab Med 1994;118:1106-1109.
11. Stump DC, Topol EJ, Chen AB, Hopkins A, Collen D. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator. Thromb Haemost 1988;59:133-137.
12. Carry M, Chorally V, Willerson JT, Weiget L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia: in vivo evidence for 5-lipoxygenase activation. Circulation 1992;85:230-236.
13. Berk BC, Weintraub W, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-172.
14. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212.
15. Kushner I, Broder ML, Karp D. Control of the acute phase response: serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest 1978;61:235-242.
16. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-505.
17. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease; the Framingham Study. JAMA 1987;258:1183-1186.
18. Thompson SG, Kienast J, Pyke SDM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
19. Meade TW, Vickers MV, Thompson SG, Seghatchian MJ. The effects of physiological levels of flbrinogen on platelet aggregation. Thromb Res 1985;38:527-534.
20. Lowe GDO, Forbes CD. Blood rheology and thrombosis. Clin Lab Haematol 1981;10:343-367.
21. Reganon E, Vila V, Aznar J, Lacueva V, Martinez V, Ruano M. Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase, increase in the rate of fibrinopeptide release. Thromb Haemost 1993;70:978-983.
22. Retzinger GS. Adsorption and coagulability of fibrinogen on atheromatous lipid surfaces. Arterioscler Thromb Vasc Biol 1995;15:786-792.
23. Le J, Vilcek J. Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989;61:588-602.
24. Jude B, Agraou B, McFadden EP, Susen S, Bauters C, Lepellyey P, Vanhaesbroucke C, Devos P, Cosson A, Asseman P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation 1994;90:1662-1668.
25. Neri Serneri GG, Abbate R, Gori AM, Attanasio M, Martini F, Giusti B, Dabizzi P, Poggesi L, Modesti PA, Trotta F, Rostagno C, Boddi M, Gensini GF. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 1993;88:790-797.
26. Ceriello A, Pirisi M, Giacomello R, Stel G, Falleti E, Motz E, Lizzio S, Gonano F, Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost 1994;71:593-595.
27. Naski MC, Shafer JA. A kinetic model for the α-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III. J Biol Chem 1992;11:1267-1274.
28. Bara L, Nicaud V, Tiret L, Cambien F, Samama MM, on behalf of the EARS group. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring: the EARS Study. Thromb Haemost 1994;71:434-440.
29. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancer 1986;2:533-537.
30. Rosenson RS, Tangney CC, Hafner JM. Intraindividual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb 1994;14:1928-1932.